The entry of entry inhibitors: a fusion of science and medicine.
about
Punica granatum (Pomegranate) juice provides an HIV-1 entry inhibitor and candidate topical microbicideNeutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitorsEarly steps of retrovirus replicative cycleThe molecular basis of HIV entryCCR5 antagonism in HIV infection: current concepts and future opportunitiesTetraspanins in viral infections: a fundamental role in viral biology?Site-Directed Antibodies against the Stem Region Reveal Low pH-Induced Conformational Changes of the Semliki Forest Virus Fusion ProteinDomain III from class II fusion proteins functions as a dominant-negative inhibitor of virus membrane fusionStructures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common ThemeDealing with low pH: entry and exit of alphaviruses and flavivirusesStructural and biological mimicry of protein surface recognition by / -peptide foldamersInterfacial Cavity Filling To Optimize CD4–Mimetic Miniprotein Interactions with HIV-1 Surface GlycoproteinEscape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness lossHIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranesMaraviroc: the evidence for its potential in the management of HIVDendritic cell immunoreceptor is a new target for anti-AIDS drug development: identification of DCIR/HIV-1 inhibitorsStructure activity relationship of dendrimer microbicides with dual action antiviral activityVirus membrane-fusion proteins: more than one way to make a hairpinUse of the quartz crystal microbalance to monitor ligand-induced conformational rearrangements in HIV-1 envelope protein gp120.Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cellsEvaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formationLlama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120IFN-alpha-induced upregulation of CCR5 leads to expanded HIV tropism in vivoHIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).Resolving the infection process reveals striking differences in the contribution of environment, genetics and phylogeny to host-parasite interactions.Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity.HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsNovel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicidesStructural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1.Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodiesMonoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus.Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1.Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5Canadian consensus guidelines for the optimal use of maraviroc in the treatment of HIV-infected adults.A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibitionRole of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patientsThe domain I-domain III linker plays an important role in the fusogenic conformational change of the alphavirus membrane fusion protein
P2860
Q24559813-57C92023-97B4-4DBD-8D57-3763813753A0Q24655129-EDD8D0BB-64E7-40F0-A2FE-4A8E2F298FEFQ24792862-9569228A-925D-41DE-96C3-81F11EB978B8Q26863686-F2F13FDB-454B-4B32-B6FA-4BB405FA1CE5Q26865457-40BAA11C-F7CC-463F-8338-DA320BFE1E52Q27470936-195AB02E-7BCE-4436-88FE-C1C5A6324B63Q27477540-7D839095-DFD6-441B-8952-FC7CF5C1A2CCQ27485039-A403A20B-2C2A-4F33-B652-BF71CE11C37DQ27487974-E204F129-BAE7-4075-9EAB-83FA9382BA9CQ27490433-DF13FF11-6433-4744-B0CD-129D4170B537Q27657158-B62EB963-86A1-4EAB-911F-08AB8DDA55F9Q27678341-F58EF60F-2BA9-457A-9D05-D5188E4D8429Q28469223-C846711A-BDC6-40D0-BCA7-D01389249129Q28473380-25F65DC7-0628-436E-B0F5-ADD9A542062AQ28476655-0D4EBABB-535F-4F3A-9ABC-A17B2467478FQ28534580-4DCD4B05-B842-48D9-B340-79DC1249AC55Q28749596-E4A70A5A-F26C-427D-AAB3-750E50304B99Q29620769-C6DAF47A-7F36-43DB-ABC9-F0C8BC2F1262Q30480515-DC363CD7-8F90-4CE9-B587-D7F692C7723DQ30859838-5A230092-2706-42EB-81C8-7DE8D6EAEB67Q33249271-368757A9-D05A-4AD9-92CE-512DEFB968A8Q33374701-9E474CBC-2AB7-4CBB-AC5F-2E1B4580F558Q33533290-6FF47B91-4EA2-4FE6-9004-4B5AF0AC1792Q33807529-140EF774-A71C-4FF8-B44D-40529CFC2DB9Q33822912-BA5720E4-0C32-4BB7-A183-818F12BE1C3CQ33826826-98D373B1-AB4C-4958-9D4D-48DD7B5E8A90Q33842057-272732F5-7292-4294-8A6A-0F23DC31BB2AQ33990552-EE44E9BB-2D46-48AA-9405-5EC3B30EDA2BQ34055847-147DD933-C3D5-4D26-8380-A2E83F58F4F5Q34064787-3E3628F4-0475-40CA-BD18-90C197C9D318Q34174815-2F712F64-C4F2-40AA-B35D-86A93B7CFC51Q34229664-02AE9230-0526-430F-865E-F0B6C80548C9Q34301708-2D3CCAEC-1494-49B5-A4D5-E47E651DC10DQ34366417-D887E475-1C85-4A28-9BD7-45E5601D86C7Q34434753-FABF5F4F-50F2-4E77-91F4-09A6A0BEF1A4Q34437126-67EEB87E-F187-470B-B55B-74874F5A40BDQ34606129-7562A94F-EDB7-4889-BAE1-5B7165C79284Q35024012-CFFCEB21-BDEC-4E67-8235-45D20F9AFCAEQ35024183-857DD13A-8C29-4D30-A8D1-28A11FCA323BQ35077572-5D25B5A1-DE4E-415B-9445-9436F085BBEB
P2860
The entry of entry inhibitors: a fusion of science and medicine.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The entry of entry inhibitors: a fusion of science and medicine.
@ast
The entry of entry inhibitors: a fusion of science and medicine.
@en
type
label
The entry of entry inhibitors: a fusion of science and medicine.
@ast
The entry of entry inhibitors: a fusion of science and medicine.
@en
prefLabel
The entry of entry inhibitors: a fusion of science and medicine.
@ast
The entry of entry inhibitors: a fusion of science and medicine.
@en
P2860
P356
P1476
The entry of entry inhibitors: a fusion of science and medicine.
@en
P2093
John P Moore
Robert W Doms
P2860
P304
10598-10602
P356
10.1073/PNAS.1932511100
P407
P577
2003-09-05T00:00:00Z